【摘要】：目的:1.探討清熱化痰法治療急性氣管-支氣管炎合并全身炎癥反應(yīng)綜合征患者(痰熱壅肺證)的臨床療效。2.通過(guò)Meta分析探究國(guó)內(nèi)外研究文獻(xiàn)關(guān)于痰熱清注射液治療全身炎癥反應(yīng)綜合征患者的臨床療效以及臨床安全性。方法:1.選取天津市南開(kāi)醫(yī)院急診科和呼吸科2014年11月至2015年11月期間收治的急性氣管-支氣管炎合并SIRS患者(痰熱壅肺證)60例,隨機(jī)分為對(duì)照組、治療組各30例;上述患者均給予西醫(yī)常規(guī)治療以及抗SIRS治療,治療組患者再加用清熱化痰中成藥。對(duì)兩組患者的治療前后的中醫(yī)證候積分、體溫(T)、心率(HR)、呼吸頻率(RR)、白細(xì)胞計(jì)數(shù)(WBC)、前降鈣素原(PCT)、C-反應(yīng)蛋白(CRP)、活化部分凝血活酶時(shí)間(APTT)、血漿凝血酶時(shí)間(TT)、血漿凝血酶原時(shí)間(PT)的變化情況以及臨床療效,統(tǒng)計(jì)后進(jìn)行對(duì)比分析;同時(shí)觀察兩組患者的并發(fā)癥及死亡情況。2.應(yīng)用計(jì)算機(jī)與手工檢索,查找國(guó)內(nèi)外的大型數(shù)據(jù)庫(kù),包括中國(guó)知網(wǎng)(CNKI)、維普期刊資源整合服務(wù)平臺(tái)(VIP)、中國(guó)生物醫(yī)學(xué)文獻(xiàn)數(shù)據(jù)庫(kù)、萬(wàn)方醫(yī)學(xué)網(wǎng)、Ovid/Pubmed以及Embase等,以“痰熱清注射液/Tanreqing injection”、“全身炎癥反應(yīng)綜合征/systemic inflammatory response syndrome/SIRS”、“Meta分析/Meta-analysis”、“臨床研究/clinical research”為檢索詞,從2000-1-1至2015-5-30公開(kāi)發(fā)表的關(guān)于痰熱清注射液對(duì)SIRS患者療效的臨床隨機(jī)對(duì)照試驗(yàn)(RCT),文獻(xiàn)語(yǔ)種為中文或英文,選用Jadad質(zhì)量評(píng)分標(biāo)準(zhǔn)對(duì)文獻(xiàn)實(shí)施質(zhì)量評(píng)估,并且應(yīng)用軟件Rv Man5.3對(duì)所有納入的研究文獻(xiàn)給予評(píng)估分析。結(jié)果:1.治療組患者治療前后的中醫(yī)證候積分、HR、T、WBC、CRP、PCT、APTT、PT的改善明顯優(yōu)于對(duì)照組,消化道出血的發(fā)生率、麻痹性腸梗阻的發(fā)生率較對(duì)照組更低,臨床總有效率明顯高于對(duì)照組;且上述比較差異均具有統(tǒng)計(jì)學(xué)意義(P0.05)。2.本次研究11篇文獻(xiàn)共811例SIRS患者最終納入,其中對(duì)照組患者396例,治療組患者415例。兩組患者均給予西醫(yī)常規(guī)抗SIRS治療,治療組患者在此基礎(chǔ)上加用痰熱清注射液。最終的Meta分析結(jié)果顯示:治療組患者的臨床總有效率明顯高于對(duì)照組,WBC水平、CRP水平、PCT水平、TNF-a水平、IL-6水平、T值較對(duì)照組下降更為明顯,且上述比較差異均具有統(tǒng)計(jì)學(xué)意義(P0.05);所有納入文獻(xiàn)中均未報(bào)告有不良反應(yīng)的發(fā)生。結(jié)論:1.清熱化痰法治療急性氣管-支氣管炎合并全身炎癥反應(yīng)綜合征患者的臨床療效明顯,不僅能夠降低患者的中醫(yī)證候積分、穩(wěn)定患者的生命體征、改善患者的炎癥反應(yīng)、血凝指標(biāo),提高臨床總有效率,尚能夠降低急性氣管-支氣管炎合并SIRS患者并發(fā)癥的發(fā)生率。2.Meta分析結(jié)果顯示:痰熱清注射液能夠減輕全身炎癥反應(yīng)綜合征患者體內(nèi)的炎癥反應(yīng),提高臨床總有效率,效果良好、可靠,并且無(wú)臨床不良反應(yīng)發(fā)生,安全性較高。3.痰熱清注射液是中成藥清熱化痰法的典型代表,能夠治療多種疾病伴隨的全身炎癥狀態(tài),方便快捷、安全有效。
[Abstract]:Purpose 1. To explore the clinical effect of clearing heat and removing phlegm in treating acute tracheobronchial bronchitis complicated with systemic inflammatory response syndrome (phlegm-heat obstruction of lung syndrome). To explore the clinical efficacy and safety of Tanreqing injection in treating patients with systemic inflammatory response syndrome by meta-analysis. Method 1: 1. From November 2014 to November 2015, 60 patients with acute trachea bronchitis complicated with Sirs (phlegm-heat obstructing lung syndrome) were randomly divided into control group (n = 30) and treatment group (n = 30). All the patients were treated with routine western medicine and anti-Sirs. The patients in the treatment group were treated with traditional Chinese medicine for clearing heat and resolving phlegm. The TCM syndromes integral before and after treatment for the two groups of patients, Changes of body temperature (T), heart rate (HR), respiratory rate (RR), leukocyte count (WBC), procalcitonin (PCT) C-reactive protein (CRP), activated partial thromboplastin time (APTT), plasma thrombin time (TT), plasma prothrombin time (PT) and clinical efficacy were observed. At the same time, the complications and death of the two groups were observed. Large databases at home and abroad were searched by computer and manual search, including CNKI, VIP, Chinese Biomedical Literature Database, Ovid / Pubmed and Embase, etc. "Tanreqing injection", "systemic inflammatory response syndrome / Sirs", "Meta-analysis / meta-analysis", "clinical study / clinical research" as the key words. A randomized controlled trial (RCT) on the efficacy of Tanreqing injection in patients with Sirs was published from January 1, 2000 to May 30, 2015.The literature was conducted in Chinese or English. Jadad quality scoring criteria were used to evaluate the quality of the literature. And the software Rv Man5.3 is applied to evaluate and analyze all the research literature involved. The result is 1: 1. The improvement of TCM syndrome score before and after treatment in the treatment group was significantly better than that in the control group. The incidence of gastrointestinal hemorrhage and the incidence of paralytic intestinal obstruction were lower and the total clinical effective rate was significantly higher than that in the control group. The differences were statistically significant (P0.05). A total of 811 Sirs patients were included in this study, including 396 patients in the control group and 415 patients in the treatment group. Both groups were treated with routine anti-Sirs therapy, and the patients in the treatment group were treated with Tanreqing injection. The results of Meta-analysis showed that the total effective rate of the patients in the treatment group was significantly higher than that in the control group. The levels of CRP and PCT, TNF-a and IL-6 levels were significantly lower in the treatment group than in the control group. The differences were statistically significant (P0.05), and no adverse reactions were reported in all the literatures. Conclusion 1. The treatment of acute tracheobronchial bronchitis with systemic inflammatory response syndrome by clearing heat and removing phlegm has obvious clinical effect. It can not only reduce the TCM syndromes of the patients, stabilize the vital signs of the patients, but also improve the inflammatory reaction of the patients. The results of Meta analysis showed that Tanreqing injection could reduce the inflammatory reaction in patients with systemic inflammatory response syndrome (Sirs), and could reduce the incidence of complications in patients with acute trachea bronchitis and Sirs. 2. The results of Meta analysis showed that Tanreqing injection could alleviate the inflammatory reaction in patients with systemic inflammatory response syndrome (Sirs). Improve the total clinical effective rate, good effect, reliable, and no clinical adverse reactions, the safety is high. 3. Tanreqing injection is a typical representative of traditional Chinese patent medicine to clear away heat and dissipate phlegm. It can treat systemic inflammation accompanied by many diseases, which is convenient, quick, safe and effective.
【學(xué)位授予單位】：天津醫(yī)科大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2016
【分類(lèi)號(hào)】：R259

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 沈清玲;;清熱化痰治療對(duì)慢性阻塞性肺疾病患者動(dòng)脈血?dú)夂秃粑δ艿挠绊慬J];中國(guó)衛(wèi)生產(chǎn)業(yè);2013年25期

2 邢淑麗;活血清熱化痰法治療慢阻肺急性感染期的實(shí)驗(yàn)研究[J];天津中醫(yī);1997年02期

3 姜俊娥;王熙梅;周少華;;清熱化痰法治療冠心病50例[J];中國(guó)社區(qū)醫(yī)師;2009年01期

4 蔣云峰;;清熱化痰方治療慢性阻塞性肺疾病急性加重期療效分析[J];實(shí)用藥物與臨床;2012年12期

5 李勇;黃振炎;;清熱化痰法治療慢性阻塞性肺疾病急性期30例臨床觀察[J];湖南中醫(yī)雜志;2013年08期

6 胡獻(xiàn)國(guó);;清熱化痰說(shuō)二瀝[J];家庭中醫(yī)藥;2011年01期

7 孫軍;張兆元;耿栓柱;;自制清熱化痰顆粒劑配合西藥治療2型糖尿病臨床觀察[J];北京中醫(yī);2006年04期

8 姜俊娥;;清熱化痰法治療冠心病50例[J];現(xiàn)代中西醫(yī)結(jié)合雜志;2007年08期

9 荊小莉;王東平;李慧;崔喜梅;高錦輝;;清熱化痰對(duì)慢性阻塞性肺疾病急性發(fā)作患者氧化應(yīng)激和炎癥的影響[J];中華臨床醫(yī)師雜志(電子版);2009年04期

10 高巧巧;;清熱化痰法治療卵巢囊腫30例[J];湖北中醫(yī)雜志;1992年03期

相關(guān)會(huì)議論文 前5條

1 毛兵;楊紅梅;廖冬雪;秦永平;;從方劑體內(nèi)有效物質(zhì)基礎(chǔ)及組織靶向性初步探討清熱化痰法治療慢性阻塞性肺疾病的機(jī)制[A];第十次全國(guó)中西醫(yī)結(jié)合防治呼吸系統(tǒng)疾病學(xué)術(shù)研討會(huì)論文集[C];2009年

2 王松齡;崔應(yīng)麟;劉偉;;清熱化痰安神顆粒的制備與治療失眠癥的療效觀察[A];2008年中國(guó)睡眠研究會(huì)第五屆學(xué)術(shù)年會(huì)論文摘要匯編[C];2008年

3 王強(qiáng);王超;李紅;吳慧軒;葛永彬;王賢良;;清熱化痰活血法治療老年急性冠脈綜合征的[A];中華醫(yī)學(xué)會(huì)第十五次全國(guó)心血管病學(xué)大會(huì)論文匯編[C];2013年

4 周春香;;宣肺清熱化痰法治療小兒肺炎(附72例療效觀察)[A];中國(guó)中醫(yī)藥學(xué)會(huì)基層中醫(yī)藥會(huì)議專(zhuān)刊[C];1997年

5 李彥霞;袁國(guó)強(qiáng);;從脈絡(luò)學(xué)說(shuō)論治慢性肺源性心臟病[A];首屆中西醫(yī)血管病學(xué)大會(huì)論文匯編[C];2013年

相關(guān)重要報(bào)紙文章 前10條

1 安徽望江 朱時(shí)祥;清熱化痰治甲亢[N];上海中醫(yī)藥報(bào);2013年

2 姜俊娥;清熱化痰法治療冠心病[N];農(nóng)村醫(yī)藥報(bào)（漢）;2009年

3 南京東南大學(xué)中大醫(yī)院中醫(yī)科 教授 竇國(guó)祥;清熱化痰話海蜇[N];家庭醫(yī)生報(bào);2005年

4 沈越;風(fēng)熱犯肺宜清熱化痰[N];醫(yī)藥養(yǎng)生保健報(bào);2007年

5 中國(guó)中醫(yī)科學(xué)院廣安門(mén)醫(yī)院 齊文升;中醫(yī)治重癥肺炎首重痰熱[N];中國(guó)中醫(yī)藥報(bào);2013年

6 石太印;夏日吃瓜正當(dāng)時(shí)[N];中國(guó)鄉(xiāng)鎮(zhèn)企業(yè)報(bào);2002年

7 木蘭;多食苦味好度夏[N];大眾衛(wèi)生報(bào);2003年

8 恒芳;盛夏吃點(diǎn)“苦” 安然度酷暑[N];中國(guó)中醫(yī)藥報(bào);2006年

9 李清;巧做健腦湯羹[N];醫(yī)藥養(yǎng)生保健報(bào);2006年

10 南京軍區(qū)福州總醫(yī)院 副主任醫(yī)師 王言貴;炎夏不妨常吃瓜[N];家庭醫(yī)生報(bào);2004年

相關(guān)博士學(xué)位論文 前1條

1 張智琳;清熱化痰法對(duì)痰熱蘊(yùn)肺型急性肺損傷治療作用的研究[D];廣州中醫(yī)藥大學(xué);2012年

相關(guān)碩士學(xué)位論文 前10條

1 汪真輝;清熱化痰法治療非小細(xì)胞肺癌患者圍手術(shù)期的臨床療效觀察[D];廣州中醫(yī)藥大學(xué);2016年

2 武珊珊;清熱化痰法治療急性氣管—支氣管炎合并SIRS患者的臨床研究及相關(guān)Meta分析[D];天津醫(yī)科大學(xué);2016年

3 謝靜文;清熱化痰法及其代表方劑研究[D];中國(guó)中醫(yī)科學(xué)院;2014年

4 吳姍;清熱化痰通腑方直腸滴注治療腦病意識(shí)障礙患者的臨床研究[D];廣西醫(yī)科大學(xué);2015年

5 趙文翰;清熱化痰法治療慢性阻塞性肺疾病急性加重期臨床觀察及其對(duì)外周血超氧化物歧化酶、脂質(zhì)過(guò)氧化物的影響[D];廣州中醫(yī)藥大學(xué);2007年

6 陳良;清熱化痰法對(duì)慢性阻塞性肺疾病急性加重期痰熱證的基礎(chǔ)與臨床研究[D];北京中醫(yī)藥大學(xué);2014年

7 周朋;清熱化痰活血法抗小兒肺炎支原體感染的臨床研究[D];山東中醫(yī)藥大學(xué);2003年

8 陸瀛;清熱化痰肅肺止咳法治療小兒急性支氣管炎痰熱證的臨床研究[D];南京中醫(yī)藥大學(xué);2010年

9 王東隸;基于形神共治原則的清熱化痰安神方治療早搏痰火擾心證的臨床研究[D];山東中醫(yī)藥大學(xué);2013年

10 易琳琳;清熱化痰法對(duì)COPD急性加重期患者血清瘦素及炎癥細(xì)胞因子表達(dá)干預(yù)的研究[D];瀘州醫(yī)學(xué)院;2011年

，

本文編號(hào)：2123295